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Abstract
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved 
as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results 
of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or 
greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared 
cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review 
briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.
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The kidney is the 6th and 13th most common site of  pri-
mary malignancy in men and women, respectively, in the 
developed world (1). Renal cell carcinoma (RCC) consti-
tutes 90% of kidney cancers (2). Novel therapeutic agents 
for RCC have a high clinical utility, as a large number of 
patients (between 25 and 30%) are found to have metastatic 
disease at diagnosis (3). Treatment with targeted therapies 
has resulted in improved patient outcomes in the context of 
advanced metastatic RCC, with randomised controlled trials 
demonstrating improvements in both progression-free and 
overall survival compared with previous standard-of-care 
systemic therapies (4).
RCC represents a heterogeneous group of cancers that 
arise from the kidney. The most common histological variant 
of RCC is clear cell RCC (ccRCC), which comprises about 
70% of RCC and has the highest metastatic potential. Other 
common subtypes include papillary RCC and chromophobe 
RCC; however, more than 15 histological subtypes have been 
described (5). The genetic basis of ccRCC is via a biallelic 
 inactivation of the von Hippel-Lindau (VHL) tumour sup-
pressor gene located on the short arm of chromosome 3 
Del Vecchio SJ and Ellis RJ
Journal of Kidney Cancer and VHL 2018; 5(4): 1–5 2
(3p25.3), which encodes for the degradation of hypoxia-in-
ducible factor. This mutation leads to disruption of the oxy-
gen-sensing pathway, thereby promoting angiogenesis and 
tumour proliferation/migration through the accumulation of 
vascular endothelial growth factor (VEGF), platelet-derived 
growth factor and fibroblast growth factor (6). Although 
VHL mutations are present in an estimated 70% of clear 
cell cancers, genetic heterogeneity is a hallmark of progres-
sive disease with several other genes responsible for disease 
advancement and resistance to therapy (7, 8). Another onco-
genic pathway implicated in ccRCC is the PI3K/Akt/mTOR 
cascade which is a known regulator of cellular metabolism 
and survival (9). Better understanding of the molecular 
signalling pathways implicated in RCC has driven the use 
and evolution of targeted therapeutics that have improved 
the standard of care for patients with advanced RCC. This 
review discusses the recently FDA-approved multi-kinase 
inhibitor, cabozantinib, and its role in the management of 
advanced RCC.
History of Therapeutics in Advanced Renal Cell 
Carcinoma
Prior to the early 2000s, systemic therapies demonstrating 
survival benefit for patients with advanced RCC were limited 
to interleukin-2 (IL-2) and interferon alpha (IFN-α) that 
achieved a response in about 20% of patients and carried 
high toxicity profiles (10). Sorafenib, the first small-mole-
cule oral multi-kinase inhibitor, gained FDA approval in 
December 2005 for the treatment of advanced RCC (11). 
The early-to-mid 2000s marked the beginning of the tyrosine 
kinase inhibitor (TKI) era for the treatment of advanced 
RCC, with TKIs appearing for the first time in European 
Association of Urology (EAU) recommendation guidelines 
for metastatic RCC therapy in 2006 (12). Large randomised 
clinical trials have since demonstrated the effectiveness of 
TKIs as a first-line therapy, with improved progression-free 
survival compared to treatment with interferon or placebo 
(13). Emerging resistance to TKIs has driven investigation 
into new molecular targets and the development of multi-ki-
nase inhibitors.
Mechanisms of Action of Cabozantinib
Cabozantinib is a multiple receptor tyrosine kinase inhib-
itor that initially gained FDA approval as a second-line 
therapy for patients with advanced RCC, who developed 
resistance to first-line agents, and has more recently gained 
approval as a first-line therapy. Targeting VEGF receptors 
1–3, AXL, MET, RET, KIT, FLT3, ROS1, MER, TYRO3, 
TRKB and TIE-2, the mechanism of cabozantinib inhibits 
both the VEGF pathways, and downstream targets MET and 
AXL which are implicated in tumour resistance in patients 
treated with VEGF therapy alone, such as sunitinib (14, 15). 
Cabozantinib is predominantly metabolised by the liver 
and is a substrate of CYP3A4. Co-administration of strong 
inducers or inhibitors of CYP3A4 should be avoided in 
patients who are prescribed cabozantinib to avoid fluctua-
tions in desired plasma concentration (16).
Use of Cabozantinib for Treating Advanced Renal 
Cell Carcinoma
The first clinical use of  cabozantinib in patients with RCC 
was in a phase I trial which included 25 patients who had 
failed standard systemic therapy (17). This trial demon-
strated promising results, with 19 patients experiencing 
tumour regression. Cabozantinib was first approved by the 
FDA (Cabometyx™) as a second-line treatment for met-
astatic ccRCC in 2016 (18), following finalisation of the 
results of  the phase III METEOR trial, which demonstrated 
benefits of  cabozantinib over everolimus in terms of progres-
sion-free survival, overall survival and radiological tumour 
response in patients who had failed to respond to at least 
one tyrosine kinase inhibitor (Table 1) (19–21). Subgroup 
analyses indicated that efficacy in patients with skeletal 
metastases was particularly significant (22). The FDA sub-
sequently approved cabozantinib as a first-line therapy for 
the management of  metastatic ccRCC, following completion 
of the phase II CABOSUN trial, which demonstrated ben-
efits of  cabozantinib compared with sunitinib (which is the 
standard first-line therapy) in terms of progression-free sur-
vival and radiological tumour response (although there was 
no benefit in overall survival) (23, 24). A recently published 
case report demonstrated promising efficacy of  cabozantinib 
in the management of  ccRCC with brain metastases, which 
constitute <8% of all metastatic ccRCC but are classically 
associated with poor prognosis due to resistance to antican-
cer therapies (25).
Clinical guidelines produced by the EAU and the European 
Society for Medical Oncology currently recommend cabozan-
tinib as a second-line therapy, following trial of combination 
therapy of ipilimumab plus nivolumab or standard tyrosine 
kinase inhibitor (26). EAU guidelines further state that, for 
patients with tumours of intermediate-poor prognosis (deter-
mined using the Heng score) (27), there is weak-level evidence 
for initiating cabozantinib as a first-line therapy in patients 
where use of ipilimumab plus nivolumab is contradicted or 
not feasible (Table 2) (26, 28).
Safety Profile and Side Effects
In both the METEOR and CABOSUN trials, there was an 
equivalent safety profile of cabozantinib and both everoli-
mus and sunitinib, with daily oral doses of cabozantinib of 
60 mg (20, 23). Adverse events associated with cabozantinib 
included hypertension, palmar-plantar erythrodyesthesia 
syndrome, diarrhoea, nausea/vomiting, anorexia/decreased 
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Table 1. Clinical trials of cabozantinib in patients with metastatic ccRCC
Study Population Design Findings
Phase I Trial (17) 25 patients with metastatic 
ccRCC who had failed 
standard systemic therapy 
(median of two prior 
systemic agents)
Phase I trial assessing 
safety and tolerability 
of 140 mg cabozantinib 
(PO daily) in patients 
with ccRCC
Safety: Adverse events were primary 
reason for discontinuation of drug for 
six patients, and dose reduction in 20 
patients.
Efficacy: Seven patients had a partial 
response, 13 patients had stable disease 
and 19 patients experienced tumour 
regression. Median progression-free 
survival was 12.9 months; median overall 
survival was 14.0 months.
Phase III Trial  
(METEOR) 
(19, 20, 21)
658 patients with 
metastatic ccRCC who 
had previously been 
treated with ≥1 VEGFR 
tyrosine kinase inhibitor 
and experienced disease 
progression within 6 
months of most recent 
treatment
Phase III randomised 
trial (1:1 randomisation 
to each arm) assessing 
efficacy of 60 mg 
cabozantinib (PO daily; 
n = 330) compared with 
10 mg everolimus (PO 
daily; n = 328) 
Primary endpoint: Progression-free 
survival—better progression-free survival 
in cabozantinib arm compared with 
everolimus arm (HR: 0.51, 95% CI: 
0.41–0.62).
Secondary endpoints: Overall survival—
better overall survival in cabozantinib 
arm compared with everolimus 
arm (HR: 0.66, 95% CI: 0.53–0.83). 
Objective response per independent 
radiology review – partial response in 
17% (95% CI: 13–22%) of patients in the 
cabozantinib arm, compared with 3% 
(95% CI: 2–6%) in the everolimus arm.
Quality-of-life: Similar responses to 
validated quality-of-life questionnaires 
between treatment arms; however, 
time to deterioration was longer in 
cabozantinib arm.
Phase II Trial 
(CABOSUN) 
(23, 24)
157 patients with 
metastatic ccRCC (with 
intermediate-poor 
prognosis) who had 
not previously received 
systemic treatment
Phase II randomised 
trial (1:1 randomisation 
to each arm) assessing 
efficacy of 60 mg 
cabozantinib (PO daily; 
n = 79) compared with 
50 mg sunitinib (PO 
daily, 4 weeks on, 2 
weeks off; n = 78) 
Primary endpoint: Progression-free 
survival—better progression-free survival 
in cabozantinib arm compared with 
sunitinib arm (HR: 0.66, 95% CI: 
0.46–0.95; updated analysis: HR: 0.48, 
95% CI: 0.31–0.74).
Secondary endpoints: Overall survival—
better overall survival in the cabozantinib 
arm compared with sunitinib arm, 
although this did not reach pre-specified or 
conventional levels of statistical significance 
(HR: 0.80, 95% CI: 0.50–1.26). Objective 
response per independent radiological 
review—complete or partial response in 
33% (95% CI: 23–44%) of patients in the 
cabozantinib arm compared with 12% (95% 
CI: 5.4–21%) in the sunitinib arm.
Safety: Similar incidence and severity 
of adverse events across both 
treatment arms.
ccRCC, clear cell renal cell carcinoma; CI, confidence interval; HR, hazard ratio; PO, per oral.
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appetite, fatigue and stomatitis/oral mucositis (29, 30). 
Prophylactic and supportive management should be initiated 
to reduce symptom burden (29). Eating should be avoided 2 
h before and 1 h after taking cabozantinib (31). If  cabozan-
tinib is poorly tolerated despite prophylactic and supportive 
management of side effects, stepwise dose reduction in 20 mg 
increments is recommended (29).
Cost-effectiveness
A recent systematic review which evaluated the cost-effective-
ness of cabozantinib compared with other second-line ther-
apies found that although cabozantinib was associated with 
favourable progression-free and overall survival, it was also 
one of the most expensive drugs (compared with everolimus, 
axitinib, nivolumab and sunitinib). In US dollars, costs of 
cabozantinib per patient per month of progression-free and 
overall survival were $17,864 and $11,166–$12,303, com-
pared with $16,889 and $8,569–$9,724 with everolimus (32).
Conclusion
There is good evidence for the use of cabozantinib as a sec-
ond-line therapy for the management of advanced RCC, and 
it may provide an alternative to ipilimumab plus nivolumab 
as a first-line agent in patients with intermediate-poor prog-
nosis. Although associated with marginally higher costs, 
randomised controlled trials of cabozantinib compared with 
standard therapeutics demonstrate evidence of improved 
progression-free and overall survival.
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